Skip to main content


BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) – Oppenheimer stock research analysts released their first quarter 2022 EPS estimates for BioMarin Pharmaceutical in a research note to investors on Thursday, July 29. Oppenheimer analyst L. Gershell expects the biotech company to post earnings per share of $ 0.18 for the quarter.

Several other research analysts also recently commented on BMRN. Jefferies Financial Group launched a cover on shares of BioMarin Pharmaceutical in a report on Thursday. They set a “buy” rating and a price target of $ 112.00 for the company. Wedbush reiterated a “buy” note and set a price target of $ 141.00 on shares of BioMarin Pharmaceutical in a report released Thursday. SVB Leerink launched coverage on shares of BioMarin Pharmaceutical in a report on Sunday, July 11. They set a “buy” rating and a price target of $ 83.62 for the company. Credit Suisse Group assumed coverage of BioMarin Pharmaceutical shares in a report released on Monday April 26. They set an “outperformance” rating and a price target of $ 102.00 for the company. Finally, Piper Sandler raised her price target on BioMarin Pharmaceutical shares from $ 112.00 to $ 119.00 and rated the stock as “overweight” in a research report on Thursday. Seven analysts rated the stock with a conservation rating and ten gave the company a buy rating. The company has a consensus rating of “Buy” and a consensus price target of $ 114.24.

The NASDAQ BMRN opened at $ 76.73 on Monday. The company has a quick ratio of 3.66, a current ratio of 5.32, and a debt ratio of 0.26. BioMarin Pharmaceutical has a 52 week low of $ 71.35 and a 52 week high of $ 124.52. The company has a market cap of $ 14.02 billion, a PE ratio of 17.89, a PEG ratio of 23.23 and a beta of 0.58. The company’s 50-day mobile average price is $ 80.59. BioMarin Pharmaceutical (NASDAQ: BMRN) last released its quarterly results on Tuesday, July 27. The biotech company reported EPS of $ 0.07 for the quarter, beating the consensus estimate of ($ 0.11) by $ 0.18. BioMarin Pharmaceutical had a net margin of 43.68% and a return on equity of 3.37%.

(A d)

The herbal industry was set on fire. Pay close attention to this stock.

In other news BioMarin Pharmaceutical, CFO Brian Mueller sold 6,709 shares of the company in a trade on Friday, May 7. The shares were sold at an average price of $ 79.50, for a total trade of $ 533,365.50. Following the completion of the transaction, the CFO now owns 31,357 shares of the company, valued at approximately $ 2,492,881.50. The sale was disclosed in a legal file with the SEC, which can be accessed through this link. Also, CEO Jean Jacques Bienaime sold 25,000 shares of the company in a trade on Friday, May 7. The stock was sold at an average price of $ 78.12, for a total transaction of $ 1,953,000.00. As a result of the transaction, the CEO now directly owns 303,839 shares of the company, valued at $ 23,735,902.68. Disclosure of this sale can be found here. In the past 90 days, insiders have sold 45,290 shares of the company valued at $ 3,541,565. 1.69% of the shares are held by insiders.

Major investors have recently bought and sold shares in the company. IMA Wealth Inc. increased its stake in BioMarin Pharmaceutical shares by 28.8% during the 1st quarter. IMA Wealth Inc. now owns 32,882 shares of the biotech company valued at $ 2,483,000 after purchasing an additional 7,350 shares during the period. Optimal Asset Management Inc. increased its stake in BioMarin Pharmaceutical by 215.7% in the 1st quarter. Optimal Asset Management Inc. now owns 18,733 shares of the biotechnology company valued at $ 1,415,000 after acquiring an additional 12,800 shares during the last quarter. Gabelli Funds LLC increased its stake in BioMarin Pharmaceutical by 530.4% in the 1st quarter. Gabelli Funds LLC now owns 34,670 shares of the biotech company valued at $ 2,618,000 after acquiring an additional 29,170 shares in the last quarter. Birch Grove Capital LP increased its stake in BioMarin Pharmaceutical by 6.0% in the 1st quarter. Birch Grove Capital LP now owns 35,350 shares of the biotech company valued at $ 2,669,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Banco Bilbao Vizcaya Argentaria SA increased its stake in BioMarin Pharmaceutical by 54.3% in the first quarter. Banco Bilbao Vizcaya Argentaria SA now owns 166,714 shares of the biotech company valued at $ 12,613,000 after acquiring an additional 58,662 shares in the last quarter. 95.67% of the shares are currently held by institutional investors and hedge funds.

About BioMarin Pharmaceutique

BioMarin Pharmaceutical Inc develops and markets therapies for people with rare diseases and serious and life-threatening medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 which is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Read more: Diversification is important in investing

History and Profit Estimates of BioMarin Pharmaceutical (NASDAQ: BMRN)

This instant news alert was powered by storytelling technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in BioMarin Pharmaceutical right now?

Before you consider BioMarin Pharmaceutical, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of … and BioMarin Pharmaceutical was not on the list.

While BioMarin Pharmaceutical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here

Leave a Reply